Merck & Co., Inc.

Global sales were $467 million, with more than 1,500 new patients receiving a prescription and over 27,000 total prescriptions dispensed in the quarter; cumulatively over 110,000 prescriptions and over 9,100 patients who have started therapy, with compliance remaining high.

we now have line of sight to over $70 billion of potential commercial opportunity by the mid-2030s, $20 billion more than just a year ago and more than double consensus 2028 peak KEYTRUDA revenue of $35 billion, with ten programs substantially derisked over the next two years.

Completed the acquisition of Sidera Therapeutics adding MK1406, formerly CD388, a potentially first-in-class long-acting antiviral for influenza prevention in high-risk individuals, with management believing MK1406 has greater than $5 billion in revenue potential.

Gardasil sales were $1 billion, a decrease of 35% driven by lower demand in China and Japan; other international markets grew 8% and US sales grew 7% largely due to price, partially offsetting the Asia headwinds.

We expect revenue to be between $65.5 and $67 billion, representing growth of 1% to 3%, and EPS of $5 to $5.15 with a midpoint of $5.08, including a one-time charge of approximately $9 billion related to the acquisition of Sidera and a headwind of approximately $2.5 billion from generic competition, IRA price setting, and the restructured agreement for Koselugo.